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AbstrAct
Objective: This update is concerned on the coronavirus disease (COVID-19) pandemic that is affecting the globe. The aim of this update is to 
summarize the up-to-date knowledge about the virus, its way of transmission, clinical features, diagnosis, and treatment.
Result: The COVID-19 is a public health threat affecting humankind currently after the emergence and spread of the novel coronavirus or the 
severe acute respiratory syndrome coronavirus 2. The virus is believed to have originated from bats and transmitted to humans. Around 1.5 
million peoples are confirmed to have the COVID-19 and more than 83000 individuals have died of it by April 8, 2020, all over the world. It is 
transmitted by inhaling or having contact with droplets. The incubation period ranges from 2-14 days. It manifests mainly with fever, non-
productive cough, and dyspnea. The polymerase chain reaction from various samples like throat swabs, nasal swabs, bronchoalveolar lavage 
fluid is used to confirm the diagnosis. High-resolution chest computerized tomography is abnormal in most patients, and typical findings are 
ground glass patchy opacities on both lungs and sub-segmental consolidation. Treatment is largely supportive. However, trials are ongoing, 
and chloroquine and hydroxychloroquine have got a lot of attention in the battle against COVID-19.
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IntroductIon
In December 2019, an outbreak of unusual pneumonia was 
reported in Wuhan, Hubei, China, with many cases linked 
to Huanan Seafood Market that sells seafood and live 
exotic animals. Two patients, who had fever, cough, and 
bilateral ground-glass opacities on both lungs with patchy 
infiltration were confirmed to have a novel coronavirus 
from the bronchoalveolar lavage sample. Both patients had 
reported independent contact history with this market.[1] 
Environmental samples (33 out of 585 samples) from the 
Huanan seafood market also tested positive, implying that 
the virus had originated from the market.[2] It is noted that 
most epidemic is caused by viral cross-species transmission 
from animals to human.
Similar viral outbreaks, albeit in a smaller range, had 
occurred during 2002/3, where severe acute respiratory 
syndrome (SARS) affected 8422 persons with 916 deaths (case 
fatality rate of 11%)).[3] Likewise, in 2012, a coronavirus caused 
respiratory illness named Middle East respiratory syndrome 
(MERS) first reported in Saudi Arabia and has affected 2494 
persons till November 2019 in 27 countries and had resulted 
in 858deaths. Both the SARS CoV and MERS-CoV have 
originated from bats and the intermediate hosts were palm 
civet cats and dromedary camels in SARS CoV and MERS-CoV 
respectively.[4-8]
The outbreak of COVID-19 is believed to be fueled by 
the migration of the Chinese for the Chinese New Year. The 
outbreak has spread to other parts of China and later to 
other countries. 
result
Virology 
Coronaviruses are enveloped positive-sense Ribonucleic 
acid (RNA) viruses ranging in size from 60 nm to 140 nm in 
diameter with spike-like projections on its surface, giving it a 
crown-like appearance under the electron microscope; hence 
the name coronavirus.[9] Alignment of the full-length genome 
sequence of the COVID-19 virus and other available genomes 
of Betacoronavirus showed the closest relationship was with the 
bat SARS-like coronavirus strain BatCov RaTG13, identity 96%.[10]
SARS-CoV-2 is closely related to two bat-derived severe acute 
respiratory syndrome-like coronaviruses, bat-SL-CoVZC45, and 
bat-SL-CoVZXC21(11). Whole-genome sequencing analysis 
of 104 strains of the COVID-19 virus isolated from patients 
in different localities with symptom onset between the end 
of December 2019 and mid-February 2020 showed 99.9% 
homology, without significant mutation.[11]
The novel coronavirus uses the same receptor, angioten-
sin-converting enzyme 2 as that for SARS-CoV and mainly 
spreads through the respiratory tract.[4]
The SARS-CoV-2 is strange with one of the hardest 
protective outer shells among coronaviruses. This implies 
that the virus may be highly resilient in saliva or other body 
fluids and outside the body. Thus, an infected body is more 
likely to shed a higher number of viral particles since it is 
more resistant to antimicrobial enzymes in body fluids. The 
viral particles are more likely to stay active for long. These 
factors could partly explain the greater contagiousness of 
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the SARS-CoV-2 as compared to its predecessors, SARS-CoV, 
and MERS-CoV.[12]
Transmission
The initial transmission is believed to be cross-species, 
from animal to human. The reservoir of SARS-CoV2 is a 
bat, as supported by phylogenetic analyses. However, the 
intermediate host that has transmitted the virus to humans 
is not identified for sure. Nevertheless, pangolins, snakes, 
and turtles might have acted as the potential intermediate 
hosts.[13] The main mechanism of transmission for the virus is 
either inhalation of droplets or direct contact with droplets. 
The majority of the transmission occurs from symptomatic 
persons. Nevertheless, the asymptomatic transmission 
has also a role in the spread of COVID-19.[14-18] The median 
duration of viral shedding was around three weeks in 
survivors, while the SARS-CoV-2 was detectable till death 
in non-survivors. The longest observed duration of viral 
shedding in survivors was 37 days, implying longer isolation 
of cases for preventing the viral spread.[19]
Family cluster transmission via close and unprotected 
exposure directly to droplets or indirectly with fomites in the 
immediate environment is the main reason for SARS-CoV-2 
transmission. Nosocomial transmission is possible; however, 
it is not a major contributor.[20,21] 
Human milk is not believed to be a vehicle of COVID-
19, and asymptomatic or mildly sick COVID-19 infected 
mother could breastfeed her newborn with the necessary 
precautions in place. However, if the mother is too sick for 
caring for the newborn, then freshly expressed breast milk 
should be given to the newborn.[22]
SARS-CoV-2 was also isolated from anal swabs of COVID-
19 infected individuals, raising a suspicion of a possible feco 
oral transmission.[23–25]
Pathogenesis and Clinical Features
Pathogenesis
Both viral and host factors play a role in the occurrence and 
development of COVID 19. The viral factors include virus type, 
mutation, viral load, viral titer, and viability of the virus in vitro. 
The host factors include genetics, age, gender, nutritional 
status, neuroendocrine-immune regulation, and physical 
status. The interaction of these two factors will determine 
the occurrences of infection, the severity of the disease and 
the likelihood of recovery and death.[26]
Both humoral and cellular immunity will be activated and 
have a role in the manifestation and containment of COVID-19 
infection. Virus-specific B and T lymphocytes mediate both 
humoral and cellular-based immunity. Like other acute viral 
infections, antibodies will be produced against SARS-CoV-2. 
Immunoglobulin M (IgM) and immunoglobulin G (IgG) will 
be apparent. IgM implies acute infection and is expected 
to disappear in 12 weeks after infection, while IgG will be 
long-lasting. It has to be determined if IgG is protective of 
re-infection.[26] The number of CD4+ and CD8+ T cells was 
found to be significantly reduced.[27] 
Clinical Features
The incubation period of SARS-CoV2 ranged from 2-14 
days, with a mean of 5.2 days.[28] The clinical spectrum of 
SARS-CoV-2 infection variable, comprising asymptomatic 
infection, mild upper respiratory tract illness, and severe 
viral pneumonia with respiratory failure and even death.[19]
More than 200 countries are affected by the COVID-19 
pandemic. Nearly 1.5 million people are infected with SARS-
CoV-2, and among them, more than 83,000 have died (as of 
April 8, 2020). United States of America, Spain, and Italy are 
among those that are highly affected by COVID-19(29). The 
following graph depicts the epidemiology of COVID-19 in 
selected world countries. 
All age groups are affected, including neonates and 
the elders.[30] It also affects pregnant women. There is no 
evidence of vertical transmission of SARS-CoV-2; however, 
an increased prevalence of preterm deliveries has been 
noted.[31,32]
The symptoms of COVID 19 include fever, non-productive 
cough, difficulty breathing, myalgia, and fatigue.[26,33,34] Less 
common symptoms of COVID-19 include sputum production, 
headache, hemoptysis, chest pain, muscle ache, rhinorrhea, 
nausea, vomiting and diarrhea.[35]
The major complications of COVID 19 are acute respiratory 
distress syndrome, acute cardiac injury, acute kidney injury, 
and shock.[35,36] 
Pathology 
Histological examination showed bilateral diffuse alveolar 
damage with cellular fibromyxoid exudates. The lung 
showed evident desquamation of pneumocytes and 
hyaline membrane formation, indicating acute respiratory 
distress syndrome. Interstitial mononuclear inflammatory 
infiltrates, dominated by lymphocytes, was seen in both 
lungs.  Multinucleated syncytial cells with atypical enlarged 
pneumocytes characterized by large nuclei, amphophilic 
granular cytoplasm, and prominent nucleoli were identified 
in the intra-alveolar spaces, showing viral cytopathic-like 
changes. No obvious intranuclear or intracytoplasmic viral 
inclusions were identified.[27]
Mortality and its Risk Factors
The time from the onset of COVID-19 symptoms till death 
ranged from 6 to 41 days, with a median of 14 days. The time 
from onset of symptom to death was shorter in those aged 
70 years or older as compared to those younger than 70 
years.[37] Older age, higher sequential organ failure (SOFA) 
score at admission, elevated d-dimer (> 1microgram/mL) 
were found to be associated with increased risk of in-hospital 
death.[19] One of the major reasons for death in COVID-19 is 
acute respiratory distress syndrome.[35,36]
Diagnosis 
If a person has symptoms suggestive of COVID-19 such as fever 
and /or respiratory symptoms like non-productive cough and 
dyspnea and having a travel history to COVID-19 affected 
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region or residing in COVID-19 affected area or having close 
contact with someone with respiratory symptoms, COVID-
19 should be suspected. Necessary precautions should be 
practiced by those giving care to such individuals.
Among the investigations required to confirm the 
diagnosis of COVID-19 are real-time reverse transcription-
polymerase chain reaction (RT-PCR) tests on throat swab, 
nasal swabs, bronchoalveolar lavage fluids, or blood samples. 
Currently, RT-PCR test remains the standard test to make a 
definitive diagnosis.[38] Other investigations that are required 
include complete blood count, which could be normal or 
could reveal decreased leukocyte count. Arterial blood gas 
analysis shall be done in those who have difficulty breathing. 
Liver and kidney function tests are other important tests. 
Chest radiography could be normal in COVID-19 
pneumonia; hence relying on it could be misleading.[39] 
However, in severe cases chest X-ray could reveal multiple 
patchy shadows in both lungs.
Chest computerized tomography is the main imaging 
technique used in the diagnosis of COVID-19. The most 
common finding is Ground-glass opacity that is mostly 
bilateral and multi-lobar. The other common finding is 
consolidation. Nevertheless, findings like discrete nodules, 
cavitations, pleural effusion, and lymphadenopathy were 
not observed in a study by Chung et al.[40]
Treatment
The majority of COVID-19 patients will be asymptomatic 
or have mild disease and will not require treatment or 
may need symptomatic treatment. However, for those 
with severe disease, different treatments will be required, 
including maintaining fluid balance, acid-base balance, 
administering oxygen, and using mechanical ventilation. 
Some of the specific management are discussed in the 
following paragraphs.
Immunosuppression could be protective of severe 
forms of COVID-19.[41] administration of lopinavir/ritonavir 
significantly decreased viral loads and no or little coronavirus 
titers were observed.[42] On the contrary, other studies 
showed no benefit from lopinavir/ ritonavir as compared to 
standard care severely sick COVID-19 patients.[43]
The other drugs that were used in COVID-19 patients 
are hydroxychloroquine and chloroquine.[44] Both drugs 
have resulted in decreased respiratory viral load after 
administration, though further studies are required in this 
regard. These drugs are primarily used in the treatment 
of rheumatologic diseases like rheumatoid arthritis and 
systemic lupus erythematosus. The widespread use of these 
drugs could result in a shortage of drugs for rheumatologic 
patients.[45,46] The addition of azithromycin to hydroxychloro-
quine was significantly more efficient for virus elimination.
[46] Ongoing clinical trials are testing the efficacy of chloro- 
quine.[47] More than twenty in vivo clinical trials are registered 
to test chloroquine and hydroxychloroquine for the treatment 
of COVID-19.[48,49]
Treatment of COVID-19 with inhalational interferon was 
not found effective, rather worsening was noticed.[50]
Hopeful drugs that may be helpful in the treatment of 
COVD-19 include Favipiravir.[51]
Traditional Chinese Medicines (TCM) has been used 
in different Chinese hospitals as an add-on therapy to 
other measures like antivirals; antibiotics and oxygen 
Figure 1: Summary of the COVID-19 epidemiology of selected countries, as of April 8, 2020
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supplementation was found to be effective. However, lack 
of control groups, absence of randomization, blinding, 
and allocation of concealment are concerns about the 
actual benefits of TCM. Additionally, the lack of clear 
evaluation indicators and the absence of long-term 
eff icacy and follow-up could be setbacks in taking 
the available pieces of evidence for granted for using 
TCMs.[34]
Prevention 
Entry screening for H1N1 Influenza during 2009 using a 
Thermal scanner at the airport had low sensitivity (only 
5.8 %).[52] Border screening with various techniques like self-
identification, thermal scanning, and/or visual inspection 
is resource-intensive. It could also consume public health 
personnel needed for other essential activities. However, it 
could be beneficial in creating awareness about the outbreak 
and/or pandemic among travelers.[53] Thermal screening 
alone for the prevention of COVID-19 is not very important 
because of the potential transmission by asymptomatic 
individuals as well.[54]
Affected countries are using different mechanisms of 
preventing and containing COVID-19 spread depending on 
their risk. Among the mechanisms used contacts tracing, self-
isolation or quarantine, promotion of public health measures, 
including handwashing, wearing personal protective 
equipment like facemasks, and social distancing. Postponing 
or canceling less important gatherings or handling it with 
video-conferencing or webinar is essential. Special emphasis 
and measures to protect or diminish transmission should be 
given to susceptible populations, including children, health 
care providers, and older adults.[55]
Limitation(s)
The COVID-19 pandemic is an emerging infection, and 
knowledge is evolving. Thus the knowledge included in this 
update could be changed shortly as more studies are done 
and made available.
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